Doc I'm talking about people who actually took one of the drugs or placebo, i.e the starting figure (n) vs completion. In this analsys Blarcamesine had 64% dosed completed vs 74% placebo. Donnanemab 75% dosed completed vs 80% placebo.
If we go with initial randomization figures then yes would be lower for both as both Blarca and Donnanemab lost about 8% of patients between intitial randomization and starting the trial. Hence my point stands that blarca wasn't that far off in completion rates from Donnamab in terms of dosed vs placebo.
On top of this, as 50mg had most of the dropouts it meant 30mg had a 70% completion rate (versus 75% placebo as stated). This means the 30mg group completion rate was the same distance apart from placebo as donnanameb was dosed to placebo (75 to 80) - both had dosed completion 5 lower than placebo.
As we know 30mg blara, beats Donnamemab vs placebo on adas cog / cdr sb / brain bleeds / brain shrinking and only 48 weeks to show the efficary rather than 18 months.
Market Data 
Markets 
AI
